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Immune dysfunction is a recognized feature of end-stage
renal disease and is increased with immunosuppressive drugs
following transplantation. Uncommon microorganisms
usually of low virulence may become major pathogens in this
clinical setting.We report the successful treatment of Myco-
plasma hominis infection of a hematoma post-renal transplant
nephrectomy, with cipro£oxacin monotherapy. Determina-
tion of the minimum inhibitory concentration (MIC) of
cipro£oxacin by breakpoint testing of the isolate and monitor-
ing of antibiotic levels played an essential part in this patient's
management.
An18-year-oldwoman received a cadaveric renal transplant
for end-stage renal disease secondary to chronic glomerulone-
phritis and accelerated hypertension. Flucloxacillin and
aztreonam were administrated as perioperative prophylaxis.
There was good initial graft function; however, acute graft
renal vein thrombosis occured, requiring graft nephrectomy
on the third day following transplantation. Immunosuppres-
sive therapy (azathioprine, cyclosporin and prednisolone) was
stopped and continuous ambulatory peritoneal dialysis
(CAPD) was recommenced. On the ¢rst day post nephrect-
omy she became pyrexial. The fever persisted despite empiri-
cal treatment with vancomycin 1g twice a day and
cipro£oxacin 400mg twice a day, intravenously, for a pre-
sumed central venous line infection. All cultures at this time
were negative. On day 8, computed tomography (CT) of the
abdomen showed an extensive mass suggestive of a hematoma
in the transplant bed. At exploratory laparotomy, the hema-
tomawas evacuated and specimens were sent for bacteriologi-
cal culture. These hematoma specimens and transplant bed
swabs were cultured routinely on blood and McConkey's agar
aerobically, and blood agar containing neomycin, anaerobi-
cally. In view of this patient's continuing pyrexia the plates
underwent prolonged incubation. After 4 days, transluscent
pin-point colonies were noted on both aerobic and anaerobic
blood agar, but no growth on McConkey's agar. These colo-
nies, which failed to stain by Gram's method, were identi¢ed
as M. hominis. Antibiotic treatment was therefore changed to
600mg clindamycin four times a day and 400mg intravenous
cipro£oxacin twice a day, on day 12. All subsequent specimens
from this patient underwent prolonged culture for the isola-
tion of M. hominis. Postoperative deep and super¢cial wound
swabs, wound drain £uid and the tip of the drain inserted into
the bed of the renal graft when the hematoma was evacuated,
were all positive for M. hominis. Notably, blood cultures,
endocervical and urethral swabs, midstream urine, peritoneal
dialysis £uid, throat and perineal swabs taken on day 12 were
culture negative for M. hominis. Antibiotic susceptibility was
determined by breakpoint sensitivity testing. The hematoma
isolate was inoculated on blood agar plates containing 1 and 4
mg/L of cipro£oxacin and incubated anaerobically for 5 days.
M. hominis grew in the absence of cipro£oxacin, but was
inhibited by the presence of 1mg/L of cipro£oxacin. After 3
days of antibiotic treatment the patient became apyrexial.
Unfortunately, on day 12 the patient developed diarrhoea due
toClostridium di¤cile, con¢rmed by a toxin-positive stool sam-
ple. She improved clinically on cipro£oxacin monotherapy
and on day 14 her treatment was changed to oral cipro£oxacin
500mg two times a day. After 48 h of this oral dose, 2 h post-
dose serum and peritoneal dialysate cipro£oxacin levels were
1.7mg/L and 2.2mg/L, respectively. Cipro£oxacinwas there-
fore increased to 750mg twice a day. She remained apyrexial
and was discharged home on day 25 to complete a total of 4
weeks of cipro£oxacin. A random serum cipro£oxacin level
on discharge was 3.4mg/L and all wound swabs were culture-
negative forM.hominis.
M. hominis is frequently isolated from the lower genitourin-
ary tract in healthy adults and is usually associated with infec-
tions of the upper genitourinary tract [1]. Increasingly, M.
hominis is implicated in extragenital infection. Sites of infec-
tion include blood, joints, central nervous system, lower
respiratory tract and surgical wound infections [2]. Of the lat-
ter category, sternotomy wound infections due to M. hominis
have been well described [3], often associated with immuno-
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suppression post-transplantation [4,5]. Hematomata infected
withM. hominis have previously been reported following pel-
vic trauma [6], liver transplantation [7] and renal transplanta-
tion [8]. In all these patients successful treatment included
drainage of the hematoma and extended antibiotic therapy. In
transplant patients a reduction in immunosuppressive therapy
has aided recovery from M. hominis infection [9]. Following
this patient's transplant nephrectomy, all immunosuppresive
drugs were stopped, although relative immunosuppression
continued by virtue of chronic renal failure.
The choice of antibiotic treatment in M. hominis infection
remains uncertain. Based on clinical experience, tetracyclines
are considered to be the standard, although the incidence of
M. hominis isolates resistant to these antibiotics is increasing
[10]. Alternatively, clindamycin has been used successfully in
combination with tetracyclines for the treatment of sternot-
omy infections [4]. Other agents with reported in-vitro activ-
ity against M. hominis are chloramphenicol and the
£uoroquinolones [11].M. hominis is resistant to b-lactam anti-
biotics and, unlikeM. pneumoniae is resistant to erythromycin.
Of the remaining macrolides,M. hominis is resistant to all 14 -
and 15-membered structures, but is sensitive to josamycin, a
16-membered product. The clinical experience with £uoro-
quinolone treatment forM. hominis infections is limited. Our
patient was successfully treatedwith a 4 -week course of cipro-
£oxacin following evacuation of the hematoma. Two patients
with pneumonia due to M. hominis post-lung transplantation
were successfully treated with 4 weeks cipro£oxacin therapy
[12]. An equal response was observed with cipro£oxacin and
doxycycline when treating aM. hominis prosthetic joint infec-
tion [13]. However, £uoroquinolone-resistant mutants of M.
hominis have been described in vitro and in vivo [14,15] and the
MIC ofM. hominis isolates vary [16].Therefore, determination
of antibiotic susceptibilities of signi¢cantM. hominis isolates is
essential for the clinical management.
Currently there is no standardization in methodology for
susceptibility testing of M. hominis. Both agar dilution and
microbroth dilution susceptibility testing techniques have
been adapted for use with mycoplasmas but are technically
demanding and time-consuming.The use of commercial kits
[17] and E tests have been evaluated for M. hominis. E test
determination of susceptibility of M. hominis to tetracycline
[18] and six £uoroquinolones [19] was shown to be compar-
able to that obtained by microbroth dilution. The breakpoint
method of antibiotic susceptibility testing was used in this
laboratory to determine the cipro£oxacin MIC of our isolate.
We found this latter method to be convenient, although the
accuracy of the test assumes a homogeneous distribution of
antibiotic throughout the agar.
Prediction of antibiotic serum levels remains extremely dif-
¢cult in patients on peritoneal dialysis; therefore evaluation of
cipro£oxacin concentrations in both blood and peritoneal
£uidwere performed, and the dosage adjusted accordingly.
The source of infection in our patient remains uncertain.
M. hominis has been isolated from the upper renal tract of renal
transplant patients [20] and a previously reported case of a
hematoma infected withM. hominis post renal transplantation
suggested that infection resulted from bacteremia secondary
tomanipulation of the renal tract [8].We think this an unlikely
source in this patient, as there was no evidence of colonization,
with endocervical and urethral swabs, and urine negative for
M. hominis. Arguably, early institution of cipro£oxacin ther-
apy may have eradicated the organism from these sites. The
introduction of M. hominis into the transplant bed from the
donor kidney is a possible explanationwhichwould neither be
screened for, nor covered by prophylactic antibiotics. Donor^
host transmission ofM. hominis has previously been described
in lung allograft recipients [13].
As emphasized in previous reports, the isolation ofM. homi-
nis is usually not included in routine diagnostic laboratory
protocols for wound infections. It is therefore suggested that
M. hominis should be considered as a possible pathogen in
infected hematomas in postoperative transplant patients parti-
cularly in apparently c`ulture-negative' infections. It is also
important that extragenital mycoplasma infection is consid-
ered as a possibility in patients, especially those known to be
immunode¢cient.
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Abacavir (ABC) (Ziagen, GlaxoWellcome) is a novel nucleo-
side analog that inhibits in a competitive fashion the HIV
reverse transcriptase by blocking dGTP incorporation into the
nascent DNA. Preliminary studies have shown that ABC has
comparable, or even greater, potency that the currently
approved nucleoside analogs, with a mean IC50 of 0.26 mmol/
L. The antiretroviral e¡ect of ABC is synergistic with the
activity of zidovudine, zalcitabine, lamivudine, stavudine and
didanosine [1]. In clinical trials ABC combined with two
other nucleosides has demonstrated to be a potent regimen for
naive patients [2], and a good alternative for intensi¢cation [3]
and simpli¢cation [4] in pretreated subjects. However, due to
cross-resistance mainly with zidovudine and lamiduvine, the
role of ABC in rescue regimens seems to be limited [5].
In the ¢rst clinical trials ABC seemed to have good toler-
ability, with adverse events that included nausea, diarrhoea,
headache, rash, malaise, asthenia and fatigue [6]. However, it
was not clear whether side-e¡ects were attributable toABC or
to other drugs [6]. Of note, 3% of these patients developed a
serious idiosyncratic hypersensitivity reaction (HSR), charac-
terized by fever, rash, gastrointestinal intolerance and/or
malaise. In most instances patients complained of more than
two symptoms [7], and HSR resolved when ABC was inter-
rupted. However, the reintroduction of the drug produced an
extremely severe and even lethal reaction [8]. Although ABC
toxicity seemed to be rare, further studies have reported rates
of drug discontinuation raising up to10^22% [7^9].
To assess the safety of ABC in the clinical practice, we have
analysed its tolerability in 172 consecutive patients who started
a regimen including ABC in our outpatient clinic. ABC (300
mg twice a day) was prescribed in most instances as part of a
rescue intervention in patients failing previous therapy
(67.5%). Alternatively, it was introduced to replace a drug
causing toxicity (20.2%) or following a simpli¢cation proto-
col in which protease inhibitors were replaced byABC main-
taining the same two nucleosides (9.1%).Treatment with ABC
had to be discontinued in 14 (8.1%). In seven (4%) patients
symptoms related to HSRwere reported: one had fever and
rash, four had only rash, and two had fever, malaise and asthe-
nia. Half of the interruptions were due to other manifesta-
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